Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23570405 | 0.91 | POLB (0.31) | — | |
| SCHEMBL19942536 | 0.81 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL19942385 | 0.76 | ALDH1A1 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL16146012 | 0.75 | EPHX1 (0.41) | SMN1; SMN2EPHX1 | |
| SCHEMBL24782517 | 0.75 | CHRNB2 (0.32) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL7909626 | 0.73 | PKM (0.36) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL16840696 | 0.72 | — | — | |
| SCHEMBL24754202 | 0.72 | — | — | |
| SCHEMBL16840698 | 0.72 | — | — | |
| SCHEMBL16840695 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136315-B2 | CXCR2 antagonist | MEDSHINE DISCOVERY INC. (CN) | 2021-10-05 | — | — | US | disclosed |
| US-20200339549-A1 | CXCR2 ANTAGONIST | Shenzhen Optimum Biological Technology Co., Ltd (CN) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136315-B2 | CXCR2 antagonist | CXCR2, CXCR3, CXCR1 | CHRNB2 1359/4885CHRNA4 2525/4885CHRNA7 1871/4885 |
| US-20200339549-A1 | CXCR2 ANTAGONIST | CXCR2, CXCR3, CXCR1 | CHRNB2 1359/4885CHRNA4 2525/4885CHRNA7 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.